Yazar "Acat, M." seçeneğine göre listele
Listeleniyor 1 - 11 / 11
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Cardiac Involvement is the Reason for Persistent Dyspnea in Post COVID-19 Patients without Pulmonary Sequelae: A Retrospective Study(OrtadogŸu Reklam Tanitim Yayincilik Turizm Egitim Insaat Sanayi ve Ticaret A.S., 2022) Çöllüoglu, T.; Acat, M.; Özsaraç, Ö.; Akin, Y.; Önalan, O.Objective: Several forms of cardiovascular involvement have been described in acute coronavirus disease-2019 (COVID-19) infection and also it has been shown that acute infection is responsible for cardiac symptoms. However, the data on cardiac involvement and associated symptoms in chronic phase remains unclear. Recent evidence have shown that the reason for persistent dyspnea can be persistent cardiac dysfunction in post COVID-19 infection. The aim of our study was to investigate the relationship between persistent dyspnea and cardiac involvement in post COVID-19 patients without pulmonary sequelae. Material and Methods: In our study, we recruited 30 post COVID-19 patients with dyspnea between January 2021 and July 2021. In all patients, the absence of pulmonary sequelae was detected with PFT and chest- CT. 2D-TTE, 2D-STE and MPS were performed for each case. Results: Left ventricular dysfunction was detected in 63.3% of patients and also 93.3% of patients had extensive abnormal GLS at 3 month follow-up. Of the patients, 33.3% had myocardial perfusion defect (MPD) and all MPDs were observed to be reversible defects. MPD was obviously seen in anterior wall (60%) and mid (20%) to apical (70%) segments. As compared with patients without MPD, patients with MPD had higher CK-MB (p: 0.016) and troponin I (p: 0.011), lesser PW thickness (p:0.020) and lower peak systolic strain rate at A2C view (p:0.031). Patients with NYHA III had more impaired GLS than patients with NYHA II (p:0.035). Conclusion: Our study suggests ischemic or non-ischemic cardiac dysfunction may be associated with persistent dyspnea in post- COVID- 19 patients without lung sequelae. © 2022 by Türkiye Klinikleri.Öğe Diagnosis of Asthma in Children(Springer International Publishing, 2021) Acat, M.; Karadag, B.The correct diagnostic approach to asthma and the exact nature of the disorder remain a matter of debate. This applies at all ages, but these issues are especially critical in childhood, the most common period for asthma to present. Over the last few decades, the concept of asthma has increasingly encompassed a more comprehensive range of presentations. It has become more heterogeneous, such that the current view of asthma is of a complicated, varied nosological concept that takes in disorders of differing aetiology yet with certain core features in common. Some researchers urge the abandonment of the term “asthma”, as the concept is losing its utility. However, at present, asthma is still used as a label for conditions in which the bronchi are obstructed to varying degrees and when no other diagnosis is likely to explain the pathological features and permit a deeper aetiological understanding [1–4]. © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2022.Öğe Diagnosis of Pulmonary Hydatid Cyst by Bronchoscopy(Lippincott Williams and Wilkins, 2015) Yasar, Z.; Acat, M.; Turgut, E.; Onaran, H.; Dincer, H.E.; Arda, N.; Çetinkaya, E.Hydatid cyst is a parasitic infestation caused by Echinococcus granulosus. Lungs are the second most common site of involvement after liver. The diagnosis of complicated pulmonary hydatid cysts may not be easy because hydatid cyst disease mimics tuberculosis, lung cancer, empyema, or abscess. Fiberoptic bronchoscopy can be a valuable tool in the diagnosis of the infestation by visualization of hydatid cyst membrane. Here, we report the case of a 33-year-old woman who presented with hemoptysis and chest discomfort and was diagnosed with a hydatid cyst by fiberoptic bronchoscopy. © 2015 Wolters Kluwer Health, Inc. All rights reserved.Öğe EVALUATION OF PRE AND POST-TREATMENT POSITRON EMISSION TOMOGRAPHY FINDINGS IN SMALL CELL LUNG CANCER(Wiley, 2014) Ozgul, G.; Toru, U.; Ozgul, M. A.; Acat, M.; Seyhan, E. C.; Annakkaya, A. N.; Ozkan, S.[No abstract available]Öğe False-positive 18-fluorodeoxyglucose positron emission tomography–computed tomography (FDG PET/CT) scans mimicking malignancies(Medical Association of Zenica-Doboj Canton, 2015) Yasar, Z.; Acat, M.; Onaran, H.; Ozgül, A.; Dincer, E.H.; Cetinkaya, E.; Korkmaz, N.A.Aim 18-Fluorodeoxyglucose (FDG) positron emission tomography–computed tomography (PET/CT) is an imaging modality that is often used to help differentiate benign from malignant pulmonary lesions and it has been shown to be more efficacious than conventional chest computed tomography (CT). However, some benign lesions may also show increased metabolic activity which can lead to false-positive PET findings. We aim to illustrate false positive findings of PET scan that simulate lung cancer in a variety of diseases. Methods Patients referred to Yedikule Chest Diseases and Surgery Teaching and Research Hospital with increased FDG uptake for which histological results were available over a 2-year period (2013-2014) were reviewed. Seven patients with false-positive PET/CT findings were reported in this study. Results The majority of lesions showing increased metabolic activity were due to malignant diseases. However, increased 18 F-FDG uptake was also seen in benign lesions such as active pulmonary inflammation or infection, granulomatous processes and fibrotic lesions. Conclusion The integration of clinical history, morphologic findings of lesions on the CT component, and metabolic activities of PET/CT scan can help reduce false interpretations. Interventional procedures may be needed for tissue confirmation for differential diagnosis. © 2015 Medical Association of Zenica-Doboj Canton. All rights reserved.Öğe High serum levels of IGF-I and IGFBP3 may increase comorbidity risk for asthmatic patients(Comenius Univ, 2017) Acat, M.; Erbay, Toru U.; Sahin, S.; Arik, O.; Ayada, C.OBJECTIVE: Asthma is known as a chronic inflammatory lung disease which has also systemic features. Insulin-like growth factor I (IGF-I) plays a role for asthma pathogenesis. Controversially, IGF-binding protein 3 (IGFBP3) blocks asthma development. That is why IGF-I and IGFBP3 are targeted for future therapeutic treatments of asthma. We aimed to investigate serum level of IGF-I and IGFBP3 in patients with asthma. This study was performed in 27 asthma and 23 healthy individuals. Serum levels of IGF-I and IGFBP3 were measured by human ELISA assay kits. Serum levels of IGF-I and IGFBP3 were significanlty higher in the asthma group than the control group. Significant negative correlation was found between IGF-I and asthma control test (ACT) puan, O-2 saturation, Forced Expiratory Volume in 1 second/ Forced Vital Capacity (FEV1/FVC), Forced Expiratory Flow 25 second/75 second (FEF2575) (%). Significant positive correlation was found between IGFBP3 and IGF-I, systolic blood pressure. Significant negative correlation was found between IGF-I and FEV1 (ml). RESULTS: Our results indicate that the serum levels of IGF-I and IGFBP3 are significanlty elevated in the asthma group. We assume that current treatment strategies are not really good enough for asthma. We suppose further strategies which are seeking to balance IGF-I and IGFBP3 should be developed for more effective and curative treatment of asthma (Tab. 2, Fig. 2, Ref. 22). Text in PDF www.elis.sk.Öğe Interventional treatment of endobronchial hamartomas and lipomas(Mattioli 1885 S.p.A., 2016) Özgül, M.A.; Çetinkaya, E.; Gül, S.; Dinçer, H.E.; Acat, M.; Boyaci, H.; Özgül, G.Objective: Endobronchial benign tumors are rarely seen in lung cancers or in pulmonary benign tumors. In recent years, endoscopic treatment has increasingly been used to treat benign endobronchial lesions. Methods: Data from all adult patients diagnosed with a histologically proven endobronchial hamartoma and lipoma were collected between 2009 and 2014 at our clinic in the Yedikule Chest Diseases Education and Research Hospital. Results: 9 patients were included in the study; 6 patients were diagnosed with endobronchial hamartoma(66%) and 3 had endobronchial lipoma. Six patients were symptomatic. All patients underwent rigid bronchoscopy and biopsies taken during treatment were diagnostic in all cases. Lesions were mostly located at the lobar bronchus. Seven (77%) cases were successfully treated and there were no complications because of the procedure. Two patients was sent for lobectomy because of inadequate debulking. Recurrence was not seen in any patient. Conclusion: Interventional bronchoscopic techniques may be a safe and effective method for diagnosing and treating endobronchial benign tumors. © Mattioli 1885.Öğe A rare case of tracheal lymphoma presenting with severe tracheal stenosis(Mattioli 1885 S.p.A., 2015) Ozgul, A.; Yasar, Z.A.; Sahin, U.; Acat, M.; Tecimer, T.; Çetinkaya, E.Primary malignant lymphoma of the trachea is rare and its underlying mechanism remains unknown. Primary tracheal tumors are also very rare causes of airway obstructions. This case report features a 60 year-old woman who presented with the complaint of dyspnea. A mass narrowing the tracheal lumen posteriorly in the subglottic area and mediastinal lymphadenopathy was detected by computed tomography scan and a rijit bronchoscopy was performed. This showed polypoid, variable-sized, irregular nodules causing narrowing of the tracheal lumen over a 3 cm segment in the middle part of the trachea and a mass protruding into the tracheal lumen from the posterior part of the proximal trachea. Multiple biopsy was carried out from the nodules and the airway obstruction was treated with Argon Plasma Coagulation (APC). After removal of the debris, tracheal lumen patency was obtained. The histopathology examination revealed a small lymphocytic primary non-Hodgkin’s lymphoma of the trachea. To our knowledge, this is the first case of small lymphocytic primary tracheal lymphoma in the literature. © Mattioli 1885.Öğe Reply(S. Karger AG, 2016) Onalan, O.; Adar, A.; Kiris, A.; Bülbül, Y.; Bektas, H.; Acat, M.; Casim, H.[No abstract available]Öğe Visfatin and ghrelin: Can they be forthcoming biomarkers or new drug targets for asthma?(E-Century Publishing Corporation, 2015) Toru, Ü.; Ayada, C.; Genç, O.; Sahin, S.; Arik, Ö.; Acat, M.; Bulut, I.Background & aim: Asthma represents chronic inflammation of the airways and is associated with bronchial hyperresponsiveness and reversible airway obstruction. A novel adipokine visfatin and an appetite-modulating hormone ghrelin play a role in several diseases related with inflammation. Although visfatin is a pro-inflammatory adipokine, ghrelin mainly exerts anti-inflammatory effects. However, very little is known about the role of visfatin and ghrelin in asthma. In the present study, we aimed to investigate the role of visfatin and ghrelin in asthma by evaluating their serum levels in asthmatic patients. Materials and methods: This study was performed on 27 asthma and 23 healthy controls. Blood samples were collected in tubes without EDTA. Serum levels of visfatin and ghrelin were measured by human ELISA assay kits. Statistical analyses were performed by SPSS 16.0 package program and differences were considered statistically significant at p < 0.05. Results: Serum levels of visfatin and ghrelin were significantly higher in asthma group (respectively; p = 0.001, p = 0.002). Conclusion: While visfatin has a pro-inflammatory role, ghrelin exerts an anti-inflammatory effect in asthma. Therefore, visfatin can be a forthcoming biomarker and ghrelin may be a new anti-inflammatory drug target to diagnose and treat asthmatic patients. © 2015, E-Century Publishing Corporation. All rights reserved.Öğe Which Came First Chicken Or Egg: Are Ghrelin And Visfatin Markers Or Results Of Asthma?(Amer Thoracic Soc, 2015) Toru, U.; Ayada, C.; Genc, O.; Sahin, S.; Arik, O.; Acat, M.[No abstract available]
